ELISA Explained: Types, Workflow, and How to Choose the Right Format

Table of Contents

The enzyme-linked immunosorbent assay (ELISA) is the workhorse of clinical and research immunoassays. It’s quantitative, scalable, and works with almost any antigen. But “ELISA” isn’t one method — it’s a family of formats, and choosing the wrong one means redesigning your assay.

The four main ELISA formats

Direct ELISA

Antigen is coated on the plate, then detected with an enzyme-conjugated primary antibody. Fast and simple, but the labeling step can reduce antibody affinity and there’s no signal amplification. Good for screening high-abundance targets.

Indirect ELISA

Antigen is coated, an unlabeled primary binds it, and a labeled secondary provides detection. The secondary amplifies signal and lets you reuse one labeled reagent across many primaries. Main downside: more cross-reactivity risk. This is the format used in most antibody titer assays.

Sandwich ELISA

Two antibodies recognizing different epitopes “sandwich” the antigen — a capture antibody on the plate and a detection antibody on top. Sandwich ELISA is the gold standard for quantifying soluble proteins like cytokines, growth factors, and biomarkers because it offers excellent specificity and dynamic range. The catch: you need a validated antibody pair.

Competitive ELISA

Sample antigen competes with a labeled antigen for a limited number of antibody binding sites. Higher signal means lower analyte — the relationship is inverse. This format is essential for small molecules (hormones, drugs, toxins) that lack two distinct epitopes for sandwich assays.

How to choose

If you need to…Use this format
Quantify a cytokine or biomarkerSandwich
Measure antibody titers in serumIndirect
Screen many samples for a single antigen quicklyDirect
Quantify small molecules (hormones, drugs)Competitive

Critical assay design considerations

  • Standard curve: Always run a 7- to 8-point dilution series of a known standard with each plate.
  • Replicates: Run samples in duplicate at minimum, triplicate for low-abundance targets.
  • Blocking: 1–5% BSA or non-fat milk in PBS — match what was used during antibody validation.
  • Plate selection: High-binding plates for proteins, medium-binding for peptides.
  • Substrate choice: TMB for HRP, pNPP for AP, or chemiluminescent/fluorescent substrates for higher sensitivity.

Reading and interpreting results

Plot OD versus standard concentration on a 4-parameter logistic curve (not linear) and interpolate sample values. Discard samples whose OD falls outside the standard curve — extrapolation introduces large errors. Calculate inter- and intra-assay CV; under 15% is acceptable for research, under 10% for clinical work.

ELISA’s flexibility is also its complexity. Match the format to the analyte, validate every reagent change, and your assay will be reliable for years.

Featured Articles

Daily Updates

Xenon Fell 30.7% After Pausing Two Depression Trials as Electra Closed 11.7% Below Its IPO Price and Grail’s Panel Neared With No Briefing Documents (September 21, 2026)

Last updated: September 21, 2026 Xenon Pharmaceuticals fell 30.7% Friday after pausing enrollment in two Phase 3 depression trials over neuropsychiatric adverse events, disclosed in the same release as its first NDA filing. Electra closed 11.7% below its $15.00 IPO price, and Grail’s Tuesday panel

Read More »
Daily Updates

The FDA Approved Ultragenyx’s Fayuvi Two Days Early as Bayer’s Kerendia Won the First Type 1 Diabetes CKD Nod in Over 30 Years and Novo Signed an Up to $1.4B Macrocycle Pact (September 18, 2026)

Last updated: September 18, 2026 The FDA approved Ultragenyx’s Fayuvi for Sanfilippo syndrome type A on September 17, two days before its September 19 action date. Bayer’s Kerendia added type 1 diabetes kidney disease, and Novo signed an up to $1.4 billion oral macrocycle pact

Read More »

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters